LOS ANGELES--(BUSINESS WIRE)--Dec. 16, 2005--Molecular Pharmacology (USA) Limited (OTCBB: MLPH) announced today that approval had been received from the Medical Ethics Committee of the Curtin University of Technology in Australia, for the commencement of a human clinical trial of MPL-TLB100, the first drug candidate to emerge from MPL’s newly acquired analgesic and anti-inflammatory product compound. The trial will be conducted in Australia by Professor Tony Wright, Head of the Department of Physiotherapy, Curtin University of Technology. MPL-TLB100 will be tested for the treatment of lateral epicondylitis, also known as “tennis elbow,” a common and painful over-use injury in which the muscles and tendons on the outside of the elbow become inflamed and tender. MPL-TLB100 is the first of several products based on the proprietary MPL-TL compound (tripeptofen) that will be entered into clinical testing. Additional trial sites and indications are being planned in Australia, Singapore and the United States.
